Abstract
Alzheimer’s disease (AD) is the most common form of dementia, a neurodegenerative disorder which is characterized not only by cognitive deterioration but also by a diversity of behavioral and psychological signs and symptoms of dementia (BPSD). BPSD in AD or other dementia subtypes such as frontotemporal dementia (FTD) or dementia with Lewy bodies (DLB) consist of delusions, hallucinations, activity disturbances, aggression/agitation, diurnal rhythm disturbances, mood disorders, apathy, and anxieties/phobias. Neuroimaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are very essential and useful imaging tools to differentially diagnose between AD and non-AD or healthy control subjects or between different dementia subtypes, such as AD and DLB or FTD. Besides their diagnostic utility, PET and SPECT are useful tools to investigate the cerebral pathophysiology of BPSD in dementia.
Below, PET and SPECT neuroimaging research in dementia spanning the last three decades has been systematically reviewed. The most commonly used PET and SPECT radioligands, as well as new developments in the field, all targeting different and unique aspects of neurodegeneration, are described. Furthermore, PET and SPECT research in BPSD with a main focus on depression, apathy, and psychosis in AD, DLB, and FTD are discussed in detail. On the whole, both PET and SPECT have demonstrated that depending on the behavioral phenomenon and dementia subtype, BPSD are the fundamental expression of very regional cerebral pathological events rather than a diffuse brain illness.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- 11C-DASB:
-
11C-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile
- 11C-PMP:
-
11C-methylpiperidin-4-yl propionate
- 11C-RAC:
-
11C-raclopride
- 123I-β-CIT:
-
123I-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane
- 123I-IBVM:
-
123I-iodobenzovesamicol
- 123I-IDEX:
-
123I-iododexetimide
- 123I-FP:
-
123I-fluoropropyl
- 123I-IMP:
-
N-isopropyl-p-123I-iodoamphetamine
- 18F-FDG:
-
18F-fluorodeoxyglucose
- 99mTc-ECD:
-
99mTechnetium-ethyl-cysteinate dimer
- 99mTc-HMPAO:
-
99mTechnetium-hexamethylpropyleneamine oxime
- 3DSRT:
-
3-D stereotactic region of interest template
- 5-HT:
-
Serotonin (5-hydroxytryptamine)
- Aβ:
-
Beta-amyloid
- ABS-score:
-
Abe’s BPSD score
- AD:
-
Alzheimer’s disease
- ADAS-(non)cog:
-
Alzheimer’s Disease Assessment Scale, (non)cognitive portion
- AD+CVD:
-
Alzheimer’s disease with cerebrovascular disease
- ADRDA:
-
Alzheimer’s Disease and Related Disorders (see NINCDS)
- ALS:
-
Amyotrophic lateral sclerosis
- ANCOG:
-
Antwerp cognition
- APOE:
-
Apolipoprotein E
- APP:
-
Amyloid precursor protein
- BA:
-
Brodmann area
- BADL:
-
Basic activities of daily living
- Behave-AD:
-
Behavioral pathology in Alzheimer’s disease rating scale
- BPSD:
-
Behavioral and psychological signs and symptoms of dementia
- BPSD-DS:
-
Behavioral and psychological signs and symptoms of dementia in Down syndrome
- bvFTD:
-
Behavioral variant frontotemporal dementia
- CBD:
-
Corticobasal degeneration
- CC:
-
Cingulate cortex
- CIS:
-
Cingulate island score
- COX:
-
Cyclooxygenase
- CMAI:
-
Cohen-Mansfield agitation inventory
- CSDD:
-
Cornell Scale for Depression in Dementia
- CSF:
-
Cerebrospinal fluid
- CVD:
-
Cerebrovascular disease
- DA:
-
Dopamine
- DAT:
-
Dopamine transporter
- DLB:
-
Dementia with Lewy bodies
- DSM-5:
-
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
- EPS:
-
Extrapyramidal symptoms
- ERDA:
-
Epidemiology research on dementia in Antwerp
- eZIS:
-
Easy Z-score imaging system
- FDDNP:
-
18F-2-(1-(2-(N-(2-fluoroethyl)-N-methylamino)naphthalene-6-yl)ethylidene)malononitrile
- FDG:
-
Fluorodeoxyglucose
- FTD:
-
Frontotemporal dementia
- FTLD:
-
Frontotemporal lobar degeneration
- GDS:
-
Geriatric depression scale
- HDS:
-
Hamilton Depression Rating Scale
- IAD:
-
Instrumental activities of daily living
- IDO:
-
Indoleamine 2,3-dioxygenase
- IMPY:
-
6-Iodo-2-(4′-dimethylamino-)phenyl-imidazo[1,2]pyridine
- LC:
-
locus coeruleus
- LOAD:
-
Late-onset Alzheimer’s disease
- MAPT:
-
Microtubule-associated protein tau
- MCI:
-
Mild cognitive impairment
- MFS:
-
Middelheim Frontality Score
- MMSE:
-
Mini-Mental State Examination
- MRB:
-
Methylreboxetine
- MXD:
-
Mixed dementia
- NE:
-
Norepinephrine
- NET:
-
Norepinephrine transporter
- NFT:
-
Neurofibrillary tangles
- NINCDS:
-
National Institute of Neurological and Communicative Disorders and Stroke (see ADRDA)
- NPI:
-
Neuropsychiatric Inventory
- NPI-C:
-
Neuropsychiatric Inventory-Clinician
- NPI-NH:
-
Neuropsychiatric Inventory-Nursing Home version
- NPI-Q:
-
Neuropsychiatric Inventory Questionnaire
- NPS:
-
Neuropsychiatric symptoms
- NSAID:
-
Nonsteroidal anti-inflammatory drugs
- PBR-TSPO:
-
Peripheral benzodiazepine receptor-translocator protein
- PD:
-
Parkinson’s disease
- PD-1:
-
Programmed death-1
- PDD:
-
Parkinson’s disease dementia
- PET:
-
Positron emission tomography
- PGRN:
-
Progranulin
- PiB:
-
Pittsburgh compound-B
- PSEN:
-
Presenilin
- PSP:
-
Progressive supranuclear palsy
- Py:
-
Person years
- RBD:
-
REM sleep behavioral disorder
- rCBF:
-
Regional cerebral blood flow
- ROI:
-
Regions of interest
- SB-13:
-
4-N-methylamino-4’-hydroxystilbene
- SD:
-
Semantic dementia
- SNCA:
-
α-Synuclein
- SPECT:
-
Single-photon emission computed tomography
- SPM:
-
Statistical parametric mapping
- TDP-43:
-
TAR DNA-binding protein 43
- U:
-
Ubiquitin
- VAD:
-
Vascular dementia
References
Aalten P, Verhey F, Boziki M et al (2007) Neuropsychiatric syndromes in dementia; results from the European Alzheimer disease consortium. Dement Geiatr Cogn Disord 24:457–463
Abe K, Yamashita T, Hishikawa N et al (2015) A new simple score (ABS) for assessing behavioral and psychological symptoms of dementia. J Neurol Sci 350:14–17
ADAPT Research Group, Martin BK, Szekely C et al (2008) Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896–905
Adlard PA, Tran BA, Finkelstein DI et al (2014) A review of β-amyloid neuroimaging in Alzheimer’s disease. Front Neurosci 8:327
Agdeppa ED, Kepe V, Liu J et al (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer’s disease. J Neurosci 21:189
Akiyama H, Barger S, Barnum S et al (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421
Akiyama H, Hashimoto H, Kawabe J et al (2008) The relationship between depressive symptoms and prefrontal hypoperfusion demonstrated by eZIS in patients with DAT. Neurosci Lett 441:328–331
Alexopoulos GS, Abrams RC, Young RC et al (1988) Cornell scale for depression in dementia. Biol Psychiatry 23:271–284
Allen NHP, Burns A (1995) The noncognitive features of dementia. Rev Clin Gerontol 5:57–75
Alzheimer’s Disease International (2015) World Alzheimer report: the global impact of dementia: an analysis of prevalence, incidence, costs and trends—executive summary. Alzheimer’s Disease International (ADI), London
American Psychiatric Association (2013) Section II: diagnostic criteria and codes, neurocognitive disorders. In: Diagnostic and statistical manual of mental disorders, 5th edn; DSM-5. American Psychiatric Association, Washington, DC. doi: https://doi.org/10.1176/appi.books.9780890425596.dsm17
Antonini A (2007) The role of 123I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. Neuropsychiatr Dis Treat 3:287–292
Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611
Arora A, Bhagat N (2016) Insight into the molecular imaging of Alzheimer’s disease. Int J Biomed Imaging 2016:7462014
Ashraf A, Fan Z, Brooks DJ et al (2015) Cortical hypermetabolism in MCI subjects: a compensatory mechanism? Eur J Nucl Med Mol Imaging 42:447–458
Bachman DL, Wolf PA, Linn RT et al (1993) Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology 43:515–519
Ballarini T, Iaccarino L, Magnani G et al (2016) Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early-onset Alzheimer’s disease. Hum Brain Mapp 37:4234–4247
Bancher C, Lassmann H, Budka H et al (1987) Neurofibrillary tangles in Alzheimer’s disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles. Acta Neuropathol 74:39–46
Barrio J, Huang S, Cole G et al (1999) PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. J Labelled Comp Radiopharm 42:194–195
Barthel H, Sabri O (2011) Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimers Dis 26:117–121
Baruch K, Deczkowska A, Rosenzweig N et al (2016) PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat Med 22:135–137
Bateman RJ, Xiong C, Benzinger TL et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804
Beeri MS, Werner P, Davidson M et al (2002) The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry 17:403–408
Benoit M, Dygai I, Migneco O et al (1999) Behavioral and psychological symptoms in Alzheimer’s disease. Relation between apathy and regional cerebral perfusion. Dement Geriatr Cogn Disord 10:511–517
Benoit M, Koulibaly PM, Migneco O et al (2002) Brain perfusion in Alzheimer’s disease with and without apathy: a SPECT study with statistical parametric mapping analysis. Psychiatr Res Neuroimaging 114:103–111
Benoit M, Clairet S, Koulibaly PM et al (2004) Brain perfusion correlates of the Apathy inventory dimensions of Alzheimer’s disease. Int J Geriatr Psychiatry 19:864–869
Bertram L, Tanzi RE (2019) Alzheimer disease risk genes: 29 and counting. Nat Rev Neurol 15:191–192
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403
Boersma F, Eefsting JA, van den Brink W et al (1998) Prevalence of dementia in a rural Netherlands population and the influence of DSM-III-R and CAMDEX criteria for the prevalence of mild and more severe forms. J Clin Epidemiol 51:189–197
Bohnen NI, Frey KA (2007) Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 9:243–257
Bonte FJ, Harris TS, Hynan LS et al (2006) Tc-99m HMPAO SPECT in the differential diagnosis of dementias with histopathological confirmation. Clin Nucl Med 31:376–378
Boundy KL, Rowe CC, Reid M, Kitchener M, Barnden L et al (1997) Comparison of cholinergic neuroreceptor SPECT with 123I-iododexemetide and 99mTc-HMPAO in the early diagnosis of Alzheimer’s disease. In: De Deyn PP, Dierckx RA, Alavi A, Pickut BA (eds) A textbook of SPECT in neurology and psychiatry. John Libbey & Company Ltd, London
Boundy KL, Barnden LR, Katsifis AG et al (2005) Reduced posterior cingulated binding of I-123-iodo-dexetimide to muscarinic receptors in mild Alzheimer’s disease. J Clin Neurosci 12:421–425
Braak E, Griffi K, Arai K et al (1999) Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 249:14–22
Braskie MN, Klunder AD, Hayashi KM et al (2010) Plaque and tangle imaging and cognition in normal aging and Alzheimer’s disease. Neurobiol Aging 31:1669–1678
Breitner JC, Baker LD, Montine TJ et al (2011) Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement 7:402–411
Brendel M, Pogarell O, Xiong G et al (2015) Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. Eur J Nucl Med Mol Imaging 42:716–724
Breteler MM, Claus JJ, van Duijn CM et al (1992) Epidemiology of Alzheimer’s disease. Epidemiol Rev 14:59–82
Breteler MM, Ott A, Hofman A (1998) The new epidemic: frequency of dementia in the Rotterdam study. Haemostasis 28:117–123
Burns A, Lawlor B, Craig S (2004) Assessment scales in old age psychiatry, 2nd edn. Martin Dunetz, London
Cagnin A, Brooks DJ, Kennedy AM et al (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461–467
Caraci F, Copani A, Nicoletti F et al (2010) Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 626:64–71
Castilla-Puentes RC, Habeych ME (2010) Subtypes of depression among patients with Alzheimer’s disease and other dementias. Alzheimers Dement 6:63–69
Charpentier P, Lavenu I, Defebvre L et al (2000) Alzheimer’s disease and frontotemporal dementia are differentiated by discriminant analysis applied to 99mTc HMPAO SPECT data. J Neurol Neurosurg Psychiatry 69:661–663
Chen CJ, Bando K, Ashino H et al (2015) In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer’s disease. J Nucl Med 56:120–126
Chetelat G, Villemagne VL, Bourgeat P et al (2010) Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 67:317–324
Chiaravalloti A, Barbagallo G, Ricci M et al (2018) Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer’s disease patients: a CSF and FDG PET study. Brain Res. 1678:116–122
Chiotis K, Stenkrona P, Almkvist O et al (2018) Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. Eur J Nucl Med Mol Imaging 45:1605–1617
Choi SR, Golding G, Zhuang ZP et al (2009) Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 50:1887–1894
Cohen-Mansfield J, Deutsch LH (1996) Agitation: subtypes and their mechanisms. Semin Clin Neuropsychiatry 1:325–339
Cohen-Mansfield J, Marx MS, Rosenthal AS (1989) A description of agitation in a nursing home. J Gerontol 44:77–84
Côté S, Carmichael PH, Verreault R et al (2012) Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer’s disease. Alzheimers Dement 8:219–226
Cruts M, Gijselinck I, van der Zee J et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924
Cummings JL, Mega MS, Gray K et al (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314
De Deyn PP (2004) Dementie—Medisch, psychosociaal, ethisch & preventief, 1st edn. Kluwer, Mechelen
De Deyn PP, Wirshing WC (2001) Scales to assess efficacy and safety of pharmacologic agents in treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry 62:19–22
De Deyn PP, Engelborghs S, Saerens J et al (2005) The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer’s disease. Int J Geriatr Psychiatry 20:70–79
De Deyn PP, Goeman J, Vervaet A et al (2011) Prevalence and incidence of dementia among 75-80-year-old community-dwelling elderly in different districts of Antwerp, Belgium: The Antwerp Cognition (ANCOG) Study. Clin Neurol Neurosurg 113:736–745
Debruyne H, Van Buggenhout M, Le Bastard N et al (2009) Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment ? Int J Geriatr Psychiatry 24:556–562
Dekker AD, Sacco S, Carfi A et al (2018) The behavioral and psychological symptoms of dementia in down syndrome (BPSD-DS) scale: comprehensive assessment of psychopathology in down syndrome. J Alzheimers Dis 63:797–820
Delrieu J, Desmidt T, Camus V et al (2015) Apathy as a feature of prodromal Alzheimer’s disease: an FDG-PET ADNI study. Int J Geriatr Psychiatry 30:470–477
Deutsch LH, Bylsma FW, Rovner BW et al (1991) Psychosis and physical aggression in probable Alzheimer’s disease. Am J Psychiatry 148:1159–1163
Devenand DP, Jacobs DM, Ming-Xin T et al (1997) The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 54:257–263
Dobos N, Korf J, Luiten PG et al (2010) Neuroinflammation in Alzheimer’s disease and major depression. Biol Psychiatry 67:503–504
Doraiswamy PM, Sperling RA, Coleman RE et al (2012) Amyloid-β assessed by florbetapir F-18-PET and 18-month cognitive decline: a multicenter study. Neurology 79:1636–1644
Du X, Wang X, Geng M (2018) Alzheimer’s disease hypothesis and related therapies. Transl Neurodegener 7:2
Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629
Engelborghs S, Marescau B, De Deyn PP (2003) Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson’s disease. Neurochem Res 28:1145–1150
Engelborghs S, Vloeberghs E, Maertens K et al (2004) Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia: a prospective study. Int J Geriatr Psychiatry 19:365–370
Engelborghs S, Maertens K, Nagels G et al (2005) Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry 20:1028–1037
Engelborghs S, Vloeberghs E, Le Bastard N et al (2008) The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int 52:1052–1060
Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 278:1349–1356
Fekkes D, van der Cammen TJ, van Loon CP et al (1998) Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J Neural Transm 105:287–294
Fernández M, Gobartt AL, Balañá M, COOPERA Study Group (2010) Behavioural symptoms in patients with Alzheimer’s disease and their association with cognitive impairment. BMC Neurol 10:87
Ferreira LK, Busatto GF (2011) Neuroimaging in Alzheimer’s disease: current role in clinical practice and potential future applications. Clinics 66:19–24
Finkel SI (2000) Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry 15:2–4
Finkel SI (2001) Behavioral and psychological symptoms of dementia. A current focus for clinicians, researchers, and caregivers. J Clin Psychiatry 62:3–6
Finkel SI, Costa e Silva J, Cohen G et al (1996) Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8:497–500
Folstein MF, Folstein SE, McHugh PR (1975) Mini mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465
Foster NL, Chase TN, Fedio P et al (1983) Alzheimer’s disease: focal cortical changes shown by positron emission tomography. Neurology 33:961–965
Foster NL, Heidebrink JL, Clark CM et al (2007) FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain 130:2616–2635
Francis PT (2009) Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol 2:77–82
Fukuhara R, Ikeda M, Nebu A et al (2001) Alteration of rCBF in Alzheimer’s disease patients with delusions of theft. Neuroreport 12:2473–2476
Galynker II, Dutta E, Vilkas N et al (2000) Hypofrontality and negative symptoms in patients with dementia of Alzheimer type. Neuropsychiatry Neuropsychol Behav Neurol 13:53–59
Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M et al (2005) Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia 43:442–449
Garcia-Alloza M, Tsang SW, Gil-Bea FJ et al (2006) Involvement of the GABAergic system in depressive symptoms of Alzheimer’s disease. Neurobiol Aging 27:1110–1117
Gauthier S, Gelinas I, Gauthier L (1997) Functional disability in Alzheimer’s disease. Int Psychogeriatr 9:163–165
Geda YE, Schneider LS, Gitlin LN et al (2013) Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement 9:602–608
Geser F, Wenning GK, Poewe W et al (2005) How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 20:11–20
Gijselinck I, Van Langenhove T, van der Zee J et al (2012) A C9orf72 promotor repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11:54–65
Goedert M (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci 354:1101–1118
Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492–501
Goto H, Ishii K, Uemura T et al (2010) Differential diagnosis of dementia with Lewy bodies and Alzheimer disease using combined MR imaging and brain perfusion single-photon emission tomography. Am J Neuroradiol 31:720–725
Grundke-Iqbal I, Iqbal K, Tung YC et al (1986) Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci 83:4913–4917
Guerreiro R, Escott-Price V, Darwent L et al (2016) Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson’s and Alzheimer’s diseases. Neurobiol Aging 38:214.e7–214.e10
Gwinn-Hardy K, Singleton AA (2002) Familial Lewy body diseases. J Geriatr Psychiatry Neurol 15:217–223
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Hanyu H, Sato T, Hirao K et al (2010) The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer’s disease: a longitudinal SPECT study. J Neurol Sci 290:96–101
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356
Harper DG, Stopa EG, McKee AC et al (2001) Differential circadian rhythm disturbances in men with Alzheimer’s disease and frontotemporal degeneration. Arch Gen Psychiatry 58:353–360
Harvey RJ, Skelton-Robinson M, Rossor MN (2003) The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 74:1206–1209
Hellwig S, Frings L, Bormann T et al (2019) Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET. Eur J Nucl Med Mol 46:312–323
Henderson AS (1990) Epidemiology in dementia disorders. Adv Neurol 51:15–25
Herholz K, Schopphoff H, Schmidt M et al (2002) Direct comparison of spatially normalized PET and SPECT scans in Alzheimer’s disease. J Nucl Med 43:21–26
Herrmann N, Lanctôt KL, Khan LR (2004) The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 16:261–276
Hirono N, Mori E, Yasuda M, Ikejiri Y et al (1998) Factors associated with psychotic symptoms in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 64:648–652
Hirono N, Mega MS, Dinov ID et al (2000) Left frontotemporal hypoperfusion in associated with aggression in patients with dementia. Arch Neurol 57:861–866
Hofman A, Rocca WA, Brayne C et al (1991) The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 20:736–748
Holmgren S, Hjorth E, Schultzberg M et al (2014) Neuropsychiatric symptoms in dementia-a role for neuroinflammation? Brain Res Bull 108:88–93
Holthoff VA, Beuthien-Baumann B, Kalbe E et al (2005) Regional cerebral metabolism in early Alzheimer’s disease with clinically significant apathy or depression. Biol Psychiatry 57:412–421
Hu XS, Okamura N, Arai H et al (2000) 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 55:1575–1577
Iaccarino L, Sala A, Caminiti SP et al (2017) The emerging role of PET imaging in dementia. F1000Res 6:1830
Imamura T, Ishii K, Sasaki M et al (1997) Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett 235:49–52
Iqbal K, Alonso Adel C, Chen S et al (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739:198–210
Ismail Z, Herrmann N, Francis PL et al (2009) A SPECT study of sleep disturbance and Alzheimer’s disease. Dement Geriatr Cogn Disord 27:254–259
Ismail Z, Nguyen MQ, Fischer CE et al (2012) Neuroimaging of delusions in Alzheimer’s disease. Psychiatry Res Neuroimaging 202:89–95
Jack CR Jr, Bennett DA, Blennow K et al (2016) A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539–547
Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562
Jansen IE, Savage JE, Watanabe K et al (2019) Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet 51:404–413
Jeste DV, Finkel SI (2000) Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 8:29–34
Johnson J, Hague SM, Hanson M et al (2004) SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 63:554–556
Johnson KA, Fox NC, Sperling RA (2012) Brain imaging in Alzheimer’s disease. Cold Spring Harb Perspect Med 2:a006213
Jost BC, Grossberg GT (1996) The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc 44:1078–1081
Kang JY, Lee JS, Kang H et al (2011) Regional cerebral blood flow abnormalities associated with apathy and depression in Alzheimer’s disease. Alzheimer Dis Assoc Disord 26:217–224
Kasanuki K, Iseki E, Ota K et al (2017) 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 44:358–365
Kataoka K, Hashimoto H, Kawabe J et al (2010) Frontal hypoperfusion in depressed patients with dementia of the Alzheimer type demonstrated on 3DSRT. Psychiatr Clin Neurosci 64:293–298
Katzman R, Lasker B, Bernstein N (1988) Advances in diagnosis of dementia: accuracy of diagnosis and consequences of misdiagnosis of disorders causing dementia. In: Terry RD (ed) Aging and the brain. Raven Press, New York, pp 17–62
Kaufer DI, Cummings JL, Christine D et al (1998) Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric inventory caregiver distress scale. J Am Geriatr Soc 46:210–215
Kaufer DI, Cummings JL, Ketchel P et al (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12:233–239
Keith AJ (2008) Frontotemporal dementia and related disorders: deciphering the enigma. Ann Neurol 64:4–14
Kepe V, Barrio JR, Huang SC et al (2006) Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci USA. 103:702–707
Khosravi M, Peter J, Wintering NA et al (2019) 18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer’s disease and mild cognitive impairment evaluation: a global quantitative analysis. J Alzheimers Dis 70:1197–1207. https://doi.org/10.3233/JAD-190220
Koppel J, Sunday S, Goldberg TE et al (2014) Psychosis in Alzheimer’s disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer’s disease neuroimaging initiative. Am J Geriatr Psychiatry 22:698–707
Korczyn AD, Halperin I (2009) Depression and dementia. J Neurol Sci 283:139–142
Kuhl DE, Koeppe RA, Minoshima S et al (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology 52:691–699
Kukull WA, Higdon R, Bowen JD et al (2002) Dementia and Alzheimer disease incidence—a prospective cohort study. Arch Neurol 59:1737–1746
Kung MP, Hou C, Zhuangn ZP et al (2004) Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissue of patients with Alzheimer’s disease. Brain Res 1025:98–105
Lanari A, Amenta F, Silvestrelli G et al (2006) Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev 127:158–165
Lanctôt KL, Herrmann N, Mazzotta P (2001) Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 13:5–21
Lanctôt KL, Herrmann N, Nadkarni NH et al (2004) Medial temporal hypoperfusion and aggression in Alzheimer disease. Arch Neurol 61:1731–1737
Lanctôt KL, Amatniek J, Ancoli-Israel S et al (2017) Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms. Alzheimers Dement (NY) 3:440–449
Launer LJ, Andersen K, Dewey ME et al (1999) Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European studies of dementia. Neurology 52:78–84
Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186
de Leon MJ, Convit A, Wolf OT et al (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci 98:10,966–10,971
Levy ML, Miller BL, Cummings JL et al (1996) Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol 53:687–690
Levy ML, Cummings JL, Fairbanks LA et al (1998) Apathy is not depression. J Neuropsychiatry Clin Neurosci 10:314–319
Levy-Cooperman N, Burhan AM, Rafi-Tari S et al (2008) Frontal lobe hypoperfusion and depressive symptoms in Alzheimer’s disease. J Psychiatry Neurosci 33:218–226
Liao YC, Liu RS, Lee YC et al (2003) Selective hypoperfusion of anterior CC in depressed AD patients: a brain SPECT finding by statistical parametric mapping. Dement Geriatr Cogn Disord 16:238–244
van der Linde RM, Dening T, Stephan BCM et al (2016) Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry 209:366–377
Little JT, Satlin A, Sunderland T et al (1995) Sundown syndrome in severely demented patients with probable Alzheimer’s disease. J Geriatr Psychiatry Neurol 8:103–106
Loo D, Copani A, Pike C et al (1993) Apoptosis is induced by B-amyloid in cultured central nervous. Proc Natl Acad Sci USA 90:7951–7955
Lowe VJ, Lundt E, Knopman D et al (2017) Comparison of [18F]Flutemetamol and [11C]Pittsburgh compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer’s disease dementia individuals. Neuroimage Clin 16:295–302
Lyketsos CG, Steele C, Galik E et al (1999) Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry 156:66–71
Lyketsos CG, Steinberg M, Tschanz JT et al (2000) Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry 157:708–714
Lyketsos CG, Carrillo MC, Ryan MJ et al (2011) Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement 7:532–539
Magistretti PJ (2006) Neuron-glia metabolic coupling and plasticity. J Exp Biol 209:2304–2311
Mann DM, Yates PO (1983) Serotonin nerve cells in Alzheimer’s disease [letter]. J Neurol Neurosurg Psychiatry 46:96
Maruyama M, Shimada H, Suhara T et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108
Mash DC, Flynn DD, Potter LT (1985) Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science 228:1115–1117
Mathis CA, Bacskai BJ, Kajdasz ST et al (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic Med Chem Lett 12:295–298
Matsuoka T, Narumoto J, Shibata K et al (2010) Insular hypoperfusion correlates with the severity of delusions in individuals with Alzheimer’s disease. Dement Geriatr Cogn Disord 29:287–293
Matthews KL, Chen CP, Esiri MM et al (2002) Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 51:407–416
Mazère J, Prunier C, Barret O et al (2008) In vivo SPECT imaging of vesicular acetylcholine transporter using [123I]-IBVM in early Alzheimer’s disease. Neuroimage 40:280–288
Mazère J, Lamare F, Allard M et al (2017) 123I-iodobenzovesamicol SPECT imaging of cholinergic systems in dementia with Lewy bodies. J Nucl Med 58:123–128
McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872
McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89:88–100
McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944
McKhann G, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendation from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269
de Medeiros K, Robert P, Gauthier S et al (2010) The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr 22:984–994
Meltzer CC, Smith G, DeKosky ST et al (1998) Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology 18:407–430
Mikkelsen K, Stojanovska L, Tangalakis K et al (2016) Cognitive decline: a vitamin B perspective. Maturitas 93:108–113
Minoshima S, Giordani B, Berent S et al (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94
Mitnitski AB, Graham JE, Mogilner AJ et al (1999) The rate of decline in function in Alzheimer’s disease and other dementias. J Gerontol A Biol Sci Med Sci 54:65–69
Monteiro IM, Boksay I, Auer SR et al (2001) Addition of a frequency-weighted score to the behavioral pathology in Alzheimer’s disease rating scale: the BEHAVE-AD-FW: methodology and reliability. Eur Psychiatry 16:5–24
Moran EK, Becker JA, Satlin A et al (2008) Psychosis of Alzheimer’s disease: gender differences in regional perfusion. Neurobiol Aging 29:1218–1225
Moreira PI, Smith MA, Zhu X et al (2005) Oxidative stress and neurodegeneration. Ann NY Acad Sci 1043:545–552
Morganti F, Soli A, Savoldelli P et al (2018) The Neuropsychiatric Inventory-Diary Rating Scale (NPI-Diary): a method for improving stability in assessing neuropsychiatric symptoms in dementia. Dement Geriatr Cogn Disord Extra 8:306–320
Mori T, Ikeda M, Fuhukara R et al (2006) Regional cerebral blood flow change in a case of Alzheimer’s disease with musical hallucinations. Eur Arch Psychiatry Clin Neurosci 256:236–239
Morris JC (1994) Differential diagnosis of Alzheimer’s disease. Clin Geriatr Med 10:257–276
Muller-Gartner HW, Wilson AA, Dannals RF et al (1992) Imaging muscarinic cholinergic receptors in the human brain in vivo with SPECT, 123I-4-iododexemitide. J Cereb Blood Flow Metab 12:562
Nagahama Y, Okina T, Suzuki N et al (2010) Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 133:557–567
Nagao M, Sugawara Y, Ikeda M et al (2006) Heterogeneity of posterior limbic perfusion in very early Alzheimer’s disease. Neurosci Res 55:285–291
Nakano S, Yamashita F, Matsuda H et al (2006a) Relationship between delusions and regional cerebral blood flow in Alzheimer’s disease. Dement Geriatr Cogn Disord 21:16–21
Nakano S, Asada T, Yamashita F et al (2006b) Relationship between antisocial behavior and regional cerebral blood flow in frontotemporal dementia. Neuroimage 32:301–306
Nakayama S, Suda A, Nakanishi A et al (2017) Galantamine response associates with agitation and the prefrontal cortex in patients with Alzheimer’s disease. J Alzheimers Dis 57:267–273
Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554
Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133
Newberg AB, Arnold SE, Wintering N et al (2012) Initial clinical comparison of 18F-florbetapir and 18F-FDG-PET in patients with Alzheimer disease and controls. J Nucl Med 53:902–907
Ng KP, Pascoal TA, Mathotaarachchi S et al (2017) Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology 88:1814–1821
Niu H, Álvarez-Álvarez I, Guillén-Grima F et al (2017) Prevalence and incidence of Alzheimer’s disease in Europe: a meta-analysis. Neurología 32:523–532
O’Brien JT, Firbank MJ, Mosimann UP et al (2005) Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Res 139:79–88
Okamura N, Harada R, Ishiki A et al (2018) The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging 6:305–316
Ono M, Saji H (2012) Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer’s disease: novel PET/SPECT imaging probes for diagnosis of Alzheimer’s disease. J Pharmacol Sci 118:338–344
Ott A, Breteler MM, van Harskamp HF et al (1995) Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam study. BMJ 310:970–973
Ouchi Y, Yoshikawa E, Futatsubashi M et al (2009) Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med 50:1260–1266
Palmer AM, Francis PT, Benton JS et al (1987) Presynaptic serotonergic dysfunction in patients with Alzheimer’s disease. J Neurochem 48:8–15
Patterson MB, Schnell AH, Martin RJ et al (1990) Assessment of behavioral and affective symptoms in Alzheimer’s disease. J Geriatr Psychiatry Neurol 3:21–30
Perani D, Cerami C, Caminiti SP et al (2016) Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging 43:499–508
Peretti DE, Vállez García D, Reesink FE et al (2019) Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies. PLoS One 14(1):e0211000
Perneczky R, Drzezga A, Boecker H et al (2008) Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement Geriatr Cogn Disord 25:531–538
Perneczky R, Drzezga A, Boecker H et al (2009) Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies. Neurobiol Aging 30:1420–1429
Peters F, Perani D, Herholz K et al (2006) Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dement Geriatr Cogn Disord 21:373–379
Pickut BA, Saerens J, Mariën P et al (1997) Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer’s type. J Nucl Med 38:929–934
Pietrzak RH, Gallezot JD, Ding YS et al (2013) Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 70:1199–1205
Ponton MO, Darcourt JL, Miller BL et al (1995) Psychometric and SPECT studies in Alzheimer’s disease with and without delusions. Neuropsychiatry Neuropsychol Behav Neurol 8:264–270
Prinz PN, Peskind ET, Vitaliano PP et al (1982) Changes in the sleep and waking EEG’s of nondemented and demented elderly subjects. J Am Geriatr Soc 30:86–93
Rackza KA, Becker G, Seese A et al (2010) Executive and behavioral deficits share common neural substrates in frontotemporal lobar degeneration—a pilot FDG-PET study. Psychiatry Res 182:274–280
Ready RE, Ott BR, Grace J et al (2003) Apathy and executive dysfunction in mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry 11:222–228
Reeves S, Brown R, Howard R et al (2009) Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer’s disease. Neurology 72:528–534
Reiman EM, Chen K, Alexander GE et al (2005) Correlations between apolipoprotein E 14 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci 102:8299–8302
Reisberg B, Borenstein J, Franssen E et al (1986) Remediable behavioral symptomatology in Alzheimer’s disease. Hosp Commun Psychiatry 37:1199–1201
Reisberg B, Borenstein J, Salob SP et al (1987) Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 48:9–15
Robert PH, Darcourt G, Koulibaly MP et al (2006) Lack of initiative and interest in Alzheimer’s disease: a SPECT study. Eur J Neurol 13:729–735
Robert PH, Onyike CU, Leentjens AFG et al (2009) Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 24:98–104
Roelands M, Wostyn P, Dom H et al (1994) The prevalence of dementia in Belgium: a population-based door-to-door survey in a rural community. Neuroepidemiology 13:155–161
Rolland Y, Gillette-Guyonnet S, Nourhashemi F et al (2003) Wandering and Alzheimer’s type disease. Descriptive study. REAL.FR research program on Alzheimer’s disease and management. Rev Med Interne 24:333–338
Rolland Y, Payoux P, Lauwers-Cances V et al (2005) A SPECT study of wandering behavior in Alzheimer’s disease. Int J Geriatr Psychiatry 20:816–820
Rollin-Sillaire A, Bombois S, Deramecourt V et al (2012) Contribution of single photon emission computed tomography to the differential diagnosis of dementia in a memory clinic. J Alzheimers Dis 30:833–845
Roselli F, Pisciotta NM, Perneczky R et al (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 24:2097–2103
Rosen J, Zubenko GS (1991) Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer’s disease. Biol Psychiatry 29:224–232
Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141:1356–1364
Rovner BW, German PS, Brant LJ et al (1991) Depression and mortality in nursing homes. JAMA 265:993–996
Sander K, Lashley T, Gami P et al (2016) Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement 12:1116–1124
Scarmeas N, Brandt J, Albert M et al (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer’s disease. Arch Neurol 62:1601–1608
Schroeter ML, Stein T, Maslowski N et al (2009) Neural correlates of Alzheimer’s disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. Neuroimage 47:1196–1206
Schroeter ML, Vogt B, Frisch S et al (2011) Dissociating behavioral disorders in early dementia—an FDG-PET study. Psychiatry Res 194:235–244
Schwartz WJ, Smith CB, Davidsen L et al (1979) Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 205:723–725
Sclan SG, Saillon A, Franssen E et al (1996) The behavioral pathology in Alzheimer’s disease rating scale (BEHAVE-AD): reliability and analysis of symptom category scores. Int J Geriatr Psychiatry 11:819–830
Sibson NR, Dhankhar A, Mason GF et al (1997) In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. Proc Natl Acad Sci 94:2699–2704
Sieben A, Van Langenhove T, Engelborghs S et al (2012) The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 124:353–372
Sierksma AS, van den Hove DL, Steinbusch HW et al (2010) Major depression, cognitive dysfunction and Alzheimer’s disease: is there a link? Eur J Pharmacol 626:72–82
Singleton A, Gwinn-Hardy K (2004) Parkinson’s disease and dementia with Lewy bodies: a difference in dose? Lancet 364:1105–1107
Small GW, Rabins PV, Barry PP et al (1997) Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American association for geriatric psychiatry, the Alzheimer’s association, and the American geriatrics society. JAMA 278:1363–1371
Smith AD (2002) Imaging the progression of AD pathology through the brain. Proc Natl Acad Sci USA 99:4135–4137
Smith MA, Casadesus G, Joseph JA et al (2002) Amyloid-β and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med. 33:1194–1199
Smith JA, Bourdet DL, Daniels OT et al (2014) Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol 18(2):pyu027
Sommerauer M, Hansen AK, Parbo P et al (2018) Decreased noradrenaline transporter density in the motor cortex of Parkinson’s disease patients. Mov Disord. 33:1006–1010
Staff RT, Shanks MF, Macintosh L et al (1999) Delusions in Alzheimer’s disease: spet evidence of right hemispheric dysfunction. Cortex 35:549–560
Starkstein SE, Vazquez S, Petracca G et al (1994) A SPECT study of delusions in Alzheimer’s disease. Neurology 44:2055–2059
Starkstein SE, Jorge R, Mizrahi R et al (2005) The construct of minor and major depression in Alzheimer’s disease. Am J Psychiatry 162:2086–2093
Steinberg M, Huibo S, Zandi P et al (2008) Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cach County Study. Int J Geriatri Psychiatry 23:170–177
Suhara T, Higuchi M, Miyoshi M (2008) Neuroimaging in dementia: in vivo amyloid imaging. Tohoku J Exp Med 215:119–124
Sultzer DL (1996) Behavioral syndrome in dementia: neuroimaging insights. Semin Clin Neuropsychiatry 1:261–271
Sultzer DL, Brown CV, Mandelkern MA et al (2003) Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer’s disease. Am J Psychiatry 160:341–349
Swearer JM (1994) Behavioral disturbances in dementia. In: Morris JC (ed) Handbook of dementing illnesses. Marcel Dekker, New York, pp 499–527
Szaruga M, Munteanu B, Lismont S et al (2017) Alzheimer’s-causing mutations shift Ab length by destabilizing g-Secretase-Abn interactions. Cell 170:443–456
Tanaka T, Meguro K, Yamaguchi S et al (2003) Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer’s disease. Ann Nucl Med 17:567–573
Tatsch K (2008) Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging 35:51–57
Thomas AJ, Hendriksen M, Piggott M et al (2006) A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer’s disease with and without depression. Neuropathol Appl Neurobiol 32:296–303
Trembath Y, Rosenberg C, Ervin JF et al (2003) Lewy body pathology is a frequent co-pathology in familial Alzheimer’s disease. Acta Neuropathol 105:484–488
Valotassiou V, Archimandritis S, Sifakis N et al (2010) Alzheimer’s disease: SPECT and PET tracers for beta-amyloid imaging. Curr Alzheimer Res 7:477–486
Van Dam D, De Deyn PP (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5:956–970
Van Mossevelde S, Engelborghs S, van der Zee J et al (2018) Genotype-phenotype links in frontotemporal lobar degeneration. Nat Rev Neurol 14:363–378
Vandenberghe R, Van Laere K, Ivanoiu A et al (2010) 18F-flutemetamol amyloid imaging in Alzheimer’s disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319–329
Vermeiren Y, De Deyn PP (2017) Targeting the norepinephrinergic system in Parkinson’s disease and related disorders: the locus coeruleus story. Neurochem Int 102:22–32
Vermeiren Y, Le Bastard N, Van Hemelrijck A et al (2013) Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimers Dement 9:488–498
Vermeiren Y, Van Dam D, Aerts T et al (2014) Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer’s disease. Neurobiol Aging 35:2691–2700
Vermeiren Y, Van Dam D, Aerts T et al (2015) The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 7(1):7. https://doi.org/10.1186/s13195-014-0090-1. eCollection 2015
Vermeiren Y, Janssens J, Aerts T et al (2016) Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer’s disease. J Alzheimers Dis 53:1079–1096
Versijpt J, Van Laere KJ, Dumont F et al (2003a) Imaging the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings. Neurobiol Aging 24:553–561
Versijpt J, Dumont F, Van Laere KJ et al (2003b) Assessment of neuroinflammation and microglial activation in Alzheimer’s disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur Neurol 50:39–47
Versporten A, Bossuyt N, Meulenberghs L et al (2005) The incidence of dementia: relationship with educational attainment. Arch Public Health 63:279–292
Villemagne VL, Ong K, Mulligan RS et al (2011) Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52:1210–1217
Vladimir NU (2007) Neuropathology, biochemistry, and biophysics of α-synuclein aggregation. J Neurochem 103:17–37
Waldemar G, Dubois B, Emre M et al (2007) Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14:1–26
Walker Z, Costa DC, Walker RWH et al (2002) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134–140
Weamer EA, Emanuel JE, Varon D et al (2009) The relationship of excess cognitive impairment in MCI and early Alzheimer’s disease to the subsequent emergence of psychosis. Int Psychogeriatr 21:78–85
Weggen SA (2001) Subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414:212–216
Weissberger GH, Melrose RJ, Narvaez TA et al (2017) 18F-fluorodeoxyglucose positron emission tomography cortical metabolic activity associated with distinct agitation behaviors in Alzheimer disease. Am J Geriatr Psychiatry 25:569–579
Wimo A, Winblad B, Aguero-Torres H et al (2003) The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 17:63–67
Witte MM, Foster NL, Fleisher AS et al (2015) Clinical use of amyloid-positron emission tomography neuroimaging: practical and bioethical considerations. Alzheimers Dement (Amst) 1:358–367
Wolk DA, Grachev ID, Buckley C et al (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68:1398–1403
Wolk DA, Zhang Z, Boudhar S et al (2012) Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 83:923–926
Wong DF, Rosenberg PB, Zhou Y et al (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 51:913–920
Wood S, Cummings JL, Hsu MA et al (2000) The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 8:75–83
Yasuno F, Matsuoka K, Miyasaka T et al (2019) Decreased perfusion of the posterior cingulate gyri shown by a cingulate island score is a possible marker of vulnerability to behavioural and psychological symptoms of Alzheimer’s disease: a pilot study. Psychogeriatrics 19:165–170
Yatham LN, Sossi V, Ding YS et al (2018) A positron emission tomography study of norepinephrine transporter occupancy and its correlation with symptom response in depressed patients treated with quetiapine XR. Int J Neuropsychopharmacol 21:108–113
Yesavage JA, Brink TL, Rose TL et al (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49
Acknowledgments
This work was supported by the Research Foundation-Flanders (FWO); the Belgian Alzheimer Research Foundation—Stichting Alzheimer Onderzoek (SAO-FRA grants #2017/0025 and #2018/0027); the Joint Programming Initiative Neurodegenerative Diseases (JPND) multinational research project HEROES (ZonMw project 733051072); the agreement between the Institute Born-Bunge and the University of Antwerp; the Medical Research Foundation Antwerp; the Thomas Riellaerts research fund; and Neurosearch Antwerp.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Vermeiren, Y., Van Dam, D., de Vries, M., De Deyn, P.P. (2021). Psychiatric Disorders in Dementia. In: Dierckx, R.A., Otte, A., de Vries, E.F.J., van Waarde, A., Sommer, I.E. (eds) PET and SPECT in Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-030-57231-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-57231-0_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57230-3
Online ISBN: 978-3-030-57231-0
eBook Packages: MedicineMedicine (R0)